NasdaqGM:RNAMBiotechs
Assessing Avidity Biosciences After Its 556.6% Surge and Bullish RNA Therapy Updates
Wondering if Avidity Biosciences is still a smart buy after its huge run, or if most of the upside is already priced in? Here is a look at what the numbers suggest about value from here.
The stock has cooled slightly in the last week, slipping about 0.1%, but it is still up 2.6% over the past month, 129.7% year to date, and 556.6% over 3 years, which indicates the market has rapidly rewritten its expectations.
That surge in optimism has been driven largely by excitement around Avidity's...